Optiscan Imaging Ltd (ASX: $OIL) announcement overview

Optiscan Imaging Ltd (ASX: $OIL) has announced the reveal of its groundbreaking new microscopic medical imaging device, InVueTM, designed to enable precision surgery by providing real-time digital pathology access directly to surgeons. The device, with a spatial resolution of 0.55, is expected to revolutionize the surgical market, particularly in cancer diagnosis and treatment. InVueTM represents a significant step forward in realizing the company's strategic goals and is a core component of Optiscan's growth strategy.

Executive Commentary on InVueTM Imaging Device

Dr Camile Farah, CEO and Managing Director of Optiscan, expressed, 'Getting our next-gen InVueTM microscopic medical imaging device to the reveal stage is a real credit to the hard work of the entire Optiscan team. The reveal is much more than just a significant milestone in the Company's growth strategy. It paves the way for a significant evolution of digital pathology and precision surgery. InVueTM will bring digital pathology insights into the operating theatre and directly into the hands of surgeons. The end-result will be enhanced speed and accuracy of treatment, which should in turn deliver improved patient outcomes.' Dr Farah also highlighted the potential benefits for cancer patients, particularly in breast cancer surgery and margin determination, emphasizing the device's ability to facilitate faster and more accurate patient care.

Summary of Optiscan's InVueTM Imaging Device Announcement

Optiscan Imaging Ltd (ASX: $OIL) has unveiled InVueTM, a next-gen microscopic medical imaging device designed to provide real-time digital pathology access directly to surgeons, enabling on-the-spot decision making, treatment adjustments, and precision surgery. The device, with a spatial resolution of 0.55, is expected to revolutionize the surgical market, particularly in cancer diagnosis and treatment. InVueTM represents a significant step forward in realizing the company's strategic goals and is a core component of Optiscan's growth strategy. The device's integration with Optiscan's cloud-based telepathology platform is anticipated to further enhance collaboration between surgeons and pathologists in real-time from anywhere in the world. Dr Camile Farah, CEO and Managing Director of Optiscan, emphasized the potential benefits for cancer patients, highlighting the device's ability to bring pathology and surgery together in the operating theatre to enhance the capabilities of both and ultimately facilitate faster and more accurate patient care.